William Blair Has Negative Outlook for ISRG Q3 Earnings

Key Points

• William Blair has lowered Intuitive Surgical's Q3 2025 earnings per share estimate from $1.62 to $1.58, reflecting a pessimistic outlook for the medical equipment provider.
• Despite a strong Q2 performance where Intuitive Surgical exceeded estimates with $2.19 earnings per share, the company faces declining earnings projections for the upcoming quarter.
• Analysts have mixed views, with Citigroup maintaining a "buy" rating and a target price of $650.00, while Deutsche Bank downgraded its rating to "sell" and reduced the target price to $440.00.

Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) - Analysts at William Blair cut their Q3 2025 earnings estimates for shares of Intuitive Surgical in a research report issued on Wednesday, July 23rd. William Blair analyst B. Vazquez now expects that the medical equipment provider will post earnings of $1.58 per share for the quarter, down from their prior forecast of $1.62. The consensus estimate for Intuitive Surgical's current full-year earnings is $6.43 per share.

A number of other research analysts also recently issued reports on ISRG. Truist Financial boosted their target price on shares of Intuitive Surgical from $590.00 to $600.00 and gave the company a "buy" rating in a research report on Wednesday, July 23rd. Royal Bank Of Canada boosted their target price on shares of Intuitive Surgical from $605.00 to $615.00 and gave the company an "outperform" rating in a research report on Wednesday, July 23rd. Erste Group Bank reiterated a "hold" rating on shares of Intuitive Surgical in a research report on Wednesday, July 23rd. Barclays dropped their target price on shares of Intuitive Surgical from $684.00 to $635.00 and set an "overweight" rating on the stock in a research report on Thursday, April 24th. Finally, Citigroup reiterated a "buy" rating and set a $650.00 target price (up previously from $590.00) on shares of Intuitive Surgical in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and fifteen have assigned a buy rating to the company's stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and an average target price of $592.05.

Intuitive Surgical Stock Performance

Shares of NASDAQ:ISRG traded up $1.70 during trading on Friday, reaching $497.56. The stock had a trading volume of 844,750 shares, compared to its average volume of 1,985,336. The firm's fifty day moving average is $529.86 and its 200 day moving average is $535.01. Intuitive Surgical has a 52 week low of $425.00 and a 52 week high of $616.00. The stock has a market cap of $178.37 billion, a price-to-earnings ratio of 69.39, a P/E/G ratio of 5.20 and a beta of 1.64.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its quarterly earnings data on Tuesday, July 22nd. The medical equipment provider reported $2.19 EPS for the quarter, beating analysts' consensus estimates of $1.93 by $0.26. Intuitive Surgical had a net margin of 28.51% and a return on equity of 14.56%. The company had revenue of $2.44 billion for the quarter, compared to analyst estimates of $2.35 billion. During the same period in the prior year, the firm posted $1.78 EPS. The company's quarterly revenue was up 21.4% on a year-over-year basis.

Institutional Investors Weigh In On Intuitive Surgical

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in Intuitive Surgical by 1.4% during the 1st quarter. Vanguard Group Inc. now owns 32,665,531 shares of the medical equipment provider's stock worth $16,178,258,000 after acquiring an additional 453,335 shares during the period. Geode Capital Management LLC raised its stake in Intuitive Surgical by 3.2% during the 4th quarter. Geode Capital Management LLC now owns 7,756,727 shares of the medical equipment provider's stock worth $4,039,200,000 after acquiring an additional 243,802 shares during the period. Norges Bank bought a new stake in Intuitive Surgical during the 4th quarter worth approximately $2,401,493,000. Invesco Ltd. raised its stake in Intuitive Surgical by 1.7% during the 1st quarter. Invesco Ltd. now owns 4,219,974 shares of the medical equipment provider's stock worth $2,090,027,000 after acquiring an additional 71,794 shares during the period. Finally, Northern Trust Corp raised its position in shares of Intuitive Surgical by 0.3% during the first quarter. Northern Trust Corp now owns 3,631,281 shares of the medical equipment provider's stock valued at $1,798,465,000 after buying an additional 11,988 shares during the last quarter. Institutional investors own 83.64% of the company's stock.

Insider Buying and Selling

In related news, SVP Mark Brosius sold 216 shares of the firm's stock in a transaction that occurred on Friday, June 6th. The shares were sold at an average price of $563.11, for a total value of $121,631.76. Following the transaction, the senior vice president owned 907 shares of the company's stock, valued at approximately $510,740.77. This trade represents a 19.23% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which can be accessed through this link. Also, Director Jami K. Nachtsheim sold 2,400 shares of the firm's stock in a transaction that occurred on Thursday, May 1st. The stock was sold at an average price of $520.00, for a total transaction of $1,248,000.00. Following the completion of the transaction, the director directly owned 6,371 shares in the company, valued at approximately $3,312,920. The trade was a 27.36% decrease in their position. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,610 shares of company stock valued at $3,858,340. 0.70% of the stock is owned by insiders.

Intuitive Surgical Company Profile

Intuitive Surgical, Inc develops, manufactures, and markets products that enable physicians and healthcare providers to enhance the quality of and access to minimally invasive care in the United States and internationally. The company offers the da Vinci Surgical System that enables complex surgery using a minimally invasive approach; and Ion endoluminal system, which extends its commercial offerings beyond surgery into diagnostic procedures enabling minimally invasive biopsies in the lung.